U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07110844) titled 'Teclistamab-Daratumumab in AL Amyloidosis' on July 25.
Brief Summary: The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis.
The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Amyloid Light-chain Amyloidosis
Intervention:
DRUG: Teclistamab
Teclistamab is a T-cell redirecting bispecific antibody (BsAb) targeting CD3 on T-cells and B-cell maturation antigen (BCMA) on plasma cells.
DRUG: Daratumumab and Hyaluronidase-fih...